An Open-Label Study to Evaluate the Long-term Safety and Efficacy of an Investigational Drug in Adults with fragile X syndrome
The purpose of this study is to find out whether an experimental drug is safe and effective for treating fragile X syndrome symptoms, when taken for as long as 24 months or until the drug becomes available on the market (whichever occurs later). In this study all study subjects will be treated with the active investigational drug for the entire study and there will be no placebo.
This product is an investigational drug that is not approved for use for the treatment of people with fragile X syndrome by the U.S. Food and Drug Administration.
This product is a drug that blocks the so-called mGluR5 receptor in the brain. A receptor can be thought of as a "lock" and this drug as a "key" which fits into the lock to stop it from being active. This drug can block the mGluR5 receptor that has increased activity in fragile X patients. By blocking this receptor, it is thought that the symptoms of fragile X syndrome may be reduced.
You may be eligible to participate in this study if you:
- Are an individuals who participated in the earlier 2212 placebo-controlled study
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.